Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 pivotal study of Radiprodil

Next Previous
Trial Profile

A phase 3 pivotal study of Radiprodil

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 29 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Radiprodil (Primary)
  • Indications Behavioural disorders; Neurodevelopmental disorders; Seizures
  • Focus Adverse reactions; Registrational; Therapeutic Use

Most Recent Events

  • 27 May 2025 According to a GRIN Therapeutics media release, company remains on track to initiate a global, pivotal Phase 3 clinical trial for radiprodil in GRIN-NDD in the third quarter of 2025.
  • 17 Mar 2025 According to a GRIN Therapeutics media release, company is on track to initiate a pivotal Phase 3 trial for radiprodil in mid-2025.
  • 09 Dec 2024 According to a GRIN Therapeutics media release, company presented an overview of the proposed design which was based on analysis of positive topline data from the Phase 1b Honeycomb trial for this trial at the American Epilepsy Society (AES) Annual Meeting in Los Angeles, California.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top